Temafloxacin (hydrochloride)
mRNA synthesis
In vitro transcription of capped mRNA with modified nucleotides and Poly(A) tail
Tyramide Signal Amplification (TSA)
TSA (Tyramide Signal Amplification), used for signal amplification of ISH, IHC and IC etc.
Phos Binding Reagent Acrylamide
Separation of phosphorylated and non-phosphorylated proteins without phospho-specific antibody
Cell Counting Kit-8 (CCK-8)
A convenient and sensitive way for cell proliferation assay and cytotoxicity assay
SYBR Safe DNA Gel Stain
Safe and sensitive stain for visualization of DNA or RNA in agarose or acrylamide gels.
Inhibitor Cocktails
Protect the integrity of proteins from multiple proteases and phosphatases for different applications.
MIC90: less than or equal to 0.06 micrograms/mL respiratory pathogens
Temafloxacin is a fluoroquinolone antibiotic.
Fluoroquinolone antibiotic is an organonitrogen heterocyclic antibiotic with a quinolone or quinolone-like moiety and have a fluorine atom attached to the central ring system.
In vitro: The in-vitro activities of temafloxacin, ciprofloxacin, and ofloxacin against gram-negative bacteria were compared. The 90% minimal inhibitory concentrations (MIC90s) of temafloxacin for respiratory pathogens were less than or equal to 0.06 micrograms/mL. Temafloxacin was also active against bacterial agents of sexually transmitted diseases, such as Neisseria gonorrhoeae and Chlamydia trachomatis [1].
In vivo: Mixed aerobic-anaerobic infection was induced by i.p. implantation of gelatin capsules containing Bacteroides fragilis, Escherichia coli, and sterile rat faeces. Temafloxacin was found to be highly active with a 90.9% cure rate in comparison with no treatment, and as active as a combination of clindamycin and gentamicin. Temafloxacin at 12 mg/dose resulted in rise to serum concentrations exceeding the MIC values of both microorganisms for at least 8 h [2].
Clinical trial: Clinical studies showed that temafloxacin has improved activity against pneumococci. Eradication rates in acute exacerbations of chronic bronchitis collated from individual studies are 98% overall and 100% in pneumococcal infections. Moreover, eradication rates in smokers and the elderly illustrate significant advantages for temafloxacin. In pneumonia, a twice-daily temafloxacin regimen has given equivalent overall results to those of amoxycillin (84.6% vs 80%) [3].
References:
[1] Hardy DJ. In vitro activity of temafloxacin against gram-negative bacteria: an overview. Am J Med. 1991 Dec 30;91(6A):19S-23S.
[2] Thadepalli H, Hajji M, Perumal VK, Chuah SK, Gollapudi S. Evaluation of temafloxacin in a rat model of intra-abdominal abscess. J Antimicrob Chemother. 1992 Jun;29(6):687-92.
[3] Ball P. The role of temafloxacin in the community setting: an overview. J Antimicrob Chemother. 1991 Dec;28 Suppl C:121-30.
Physical Appearance | A crystalline solid |
Storage | Store at -20°C |
M.Wt | 453.8 |
Cas No. | 105784-61-0 |
Formula | C21H18F3N3O3·HCl |
Synonyms | A-62254 |
Solubility | ≤2mg/ml in DMSO;5mg/ml in dimethyl formamide |
Chemical Name | 1-(2,4-difluorophenyl)-6-fluoro-1,4-dihydro-7-(3-methyl-1-piperazinyl)-4-oxo-3-quinolinecarboxylic acid, monohydrochloride |
SDF | Download SDF |
Canonical SMILES | CC1CN(C2=C(F)C=C(C(C(C(O)=O)=CN3C4=CC=C(F)C=C4F)=O)C3=C2)CCN1.Cl |
运输条件 | 蓝冰运输或根据您的需求运输。 |
一般建议 | 不同厂家不同批次产品溶解度各有差异,仅做参考。若实验所需浓度过大至产品溶解极限,请添加助溶剂助溶或自行调整浓度。溶液形式一般不宜长期储存,请尽快用完。 |
细胞实验 [1]: | |
细胞系 |
流感嗜血杆菌,卡他莫拉氏菌,百日咳博德特氏菌, 副百日咳博德特氏菌,脑膜炎奈瑟菌 |
溶解方法 |
在DMSO中的溶解度≤2mg/ml。为了获得更高的浓度,可以将离心管在37℃加热10分钟和/或在超声波浴中震荡一段时间。原液可以在-20℃以下储存几个月。 |
反应条件 |
0~2 μg/ml |
应用 |
Temafloxacin对呼吸道病原体如流感嗜血杆菌,卡他莫拉菌,脑膜炎奈瑟菌,百日咳博德特氏菌和嗜肺军团菌的最低抑菌浓度为(MIC90s)≤0.06 μg/ mL。Temafloxacin还具有抵抗性传播疾病细菌的作用,包括淋病奈瑟菌(MIC90≤0.015μg/ mL)和沙眼衣原体(MIC90 0.25μg/ mL)。 |
动物实验 [2]: | |
动物模型 |
大鼠腹腔内脓肿模型 |
剂量 |
12 mg/dose |
应用 |
与未经治疗相比,发现temafloxacin具有很高的活性,治愈率为90.9%,并且与克林霉素和庆大霉素的组合活性相当。剂量为12 mg /剂的temafloxacin导致血清浓度升高,超过至少8h的两种微生物的MIC值。 |
注意事项 |
请测试所有化合物在室内的溶解度,实际溶解度和理论值可能略有不同,这是由实验系统的误差引起的,属于正常现象。 |
References: [1]. Hardy DJ. In vitro activity of temafloxacin against gram-negative bacteria: an overview. Am J Med. 1991 Dec 30;91(6A):19S-23S. doi: 10.1016/0002-9343(91)90304-g. PMID: 1662890. [2]. Thadepalli H, Hajji M, Perumal VK, Chuah SK, Gollapudi S. Evaluation of temafloxacin in a rat model of intra-abdominal abscess. J Antimicrob Chemother. 1992 Jun;29(6):687-92. doi: 10.1093/jac/29.6.687. PMID: 1324241. |